B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.